(Q34547156)

2 August 2017

1 reference

title

Myopathy and rhabdomyolysis with lipid-lowering drugs (English)

1 reference

2 August 2017

1 reference

Christian Hodel

1

1 reference

2 August 2017

1 March 2002

1 reference

2 August 2017

1 reference

2 August 2017

128

1 reference

2 August 2017

159-168

1 reference

2 August 2017

1-3

1 reference

Clofibrate-induced myotoxicity in rats. Temporal profile of myopathology.

2 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0378-4274%2802%2900010-3

7 January 2021

Lovastatin and rhabdomyolysis

1 reference

https://api.crossref.org/works/10.1016%2FS0378-4274%2802%2900010-3

7 January 2021

Rhabdomyolysis in a patient receiving the combination of cerivastatin and gemfibrozil.

1 reference

https://api.crossref.org/works/10.1016%2FS0378-4274%2802%2900010-3

7 January 2021

Stereospecificity of the chloride ion channel: the action of chiral clofibric acid analogues

1 reference

https://api.crossref.org/works/10.1016%2FS0378-4274%2802%2900010-3

7 January 2021

Comparative toxicity and safety profile of fenofibrate and other fibric acid derivatives

1 reference

https://api.crossref.org/works/10.1016%2FS0378-4274%2802%2900010-3

7 January 2021

Complications during clofibrate treatment of nephrotic-syndrome hyperlipoproteinaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0378-4274%2802%2900010-3

7 January 2021

Enantiomers of clofibric acid analogs have opposite actions on rat skeletal muscle chloride channels

1 reference

https://api.crossref.org/works/10.1016%2FS0378-4274%2802%2900010-3

7 January 2021

An investigation into the role of rat skeletal muscle as a site for xenobiotic metabolism using microsomes and isolated cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0378-4274%2802%2900010-3

7 January 2021

Malignant hyperthermia

1 reference

https://api.crossref.org/works/10.1016%2FS0378-4274%2802%2900010-3

7 January 2021

Clofibrate, nephrotic syndrome, and histological changes in muscle

1 reference

https://api.crossref.org/works/10.1016%2FS0378-4274%2802%2900010-3

7 January 2021

Creatinine rise after fibrate therapy in renal graft recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0378-4274%2802%2900010-3

7 January 2021

Judicious evaluation of adverse drug reactions: inaccurate assessment of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor-induced muscle injury

1 reference

https://api.crossref.org/works/10.1016%2FS0378-4274%2802%2900010-3

7 January 2021

Letter: Acute-on-chronic renal failure precipitated by clofibrate

1 reference

https://api.crossref.org/works/10.1016%2FS0378-4274%2802%2900010-3

7 January 2021

Clofibrate-induced myotonia in the rat

1 reference

https://api.crossref.org/works/10.1016%2FS0378-4274%2802%2900010-3

7 January 2021

Hyperkalemia during treatment with HMG-CoA reductase inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0378-4274%2802%2900010-3

7 January 2021

Dissociation of hypolipidemic and antiplatelet actions from adverse myotonic effects of clofibric acid related enantiomers

1 reference

https://api.crossref.org/works/10.1016%2FS0378-4274%2802%2900010-3

7 January 2021

Adam (MDMA) and Eve (MDEA) misuse: an immunohistochemical study on three fatal cases

1 reference

https://api.crossref.org/works/10.1016%2FS0378-4274%2802%2900010-3

7 January 2021

Rhabdomyolysis with acute renal insufficiency: role of the association of fibrate and hypothyroidism

1 reference

https://api.crossref.org/works/10.1016%2FS0378-4274%2802%2900010-3

7 January 2021

Myopathy as possible side-effect of cyclosporin

1 reference

https://api.crossref.org/works/10.1016%2FS0378-4274%2802%2900010-3

7 January 2021

Does hypothyroidism potentialize muscular toxicity of fibrates?

1 reference

https://api.crossref.org/works/10.1016%2FS0378-4274%2802%2900010-3

7 January 2021

Abstracts: decline and fall

1 reference

https://api.crossref.org/works/10.1016%2FS0378-4274%2802%2900010-3

7 January 2021

Delayed toxic reaction following massive bee envenomation

1 reference

https://api.crossref.org/works/10.1016%2FS0378-4274%2802%2900010-3

7 January 2021

Myotonia induced with clofibrate in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0378-4274%2802%2900010-3

7 January 2021

Acute Muscular Syndrome Associated with Administration of Clofibrate

1 reference

https://api.crossref.org/works/10.1016%2FS0378-4274%2802%2900010-3

7 January 2021

Drug-induced myopathies

1 reference

https://api.crossref.org/works/10.1016%2FS0378-4274%2802%2900010-3

7 January 2021

Salicylate-induced rhabdomyolysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0378-4274%2802%2900010-3

7 January 2021

Rhabdomyolysis associated with concomitant use of atorvastatin and cyclosporine

1 reference

https://api.crossref.org/works/10.1016%2FS0378-4274%2802%2900010-3

7 January 2021

Extended clinical safety profile of lovastatin

1 reference

https://api.crossref.org/works/10.1016%2FS0378-4274%2802%2900010-3

7 January 2021

Rhabdomyolysis and acute renal failure induced by combination lovastatin and gemfibrozil therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0378-4274%2802%2900010-3

7 January 2021

Adverse effects of drugs on muscle

1 reference

https://api.crossref.org/works/10.1016%2FS0378-4274%2802%2900010-3

7 January 2021

Myolysis and acute renal failure in a heart-transplant recipient receiving lovastatin

1 reference

https://api.crossref.org/works/10.1016%2FS0378-4274%2802%2900010-3

7 January 2021

Rhabdomyolysis and HMG-CoA reductase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0378-4274%2802%2900010-3

7 January 2021

Mode of inhibition of mitochondrial energy transduction by chlorophenoxyisobutyrate

1 reference

https://api.crossref.org/works/10.1016%2FS0378-4274%2802%2900010-3

7 January 2021

Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0378-4274%2802%2900010-3

7 January 2021

Experimental evaluation of the effects of pravastatin on electrophysiological parameters of rat skeletal muscle

1 reference

https://api.crossref.org/works/10.1016%2FS0378-4274%2802%2900010-3

7 January 2021

Survival after massive ecstasy overdose

1 reference

https://api.crossref.org/works/10.1016%2FS0378-4274%2802%2900010-3

7 January 2021

Lovastatin, nicotinic acid, and rhabdomyolysis

1 reference

https://api.crossref.org/works/10.1016%2FS0378-4274%2802%2900010-3

7 January 2021

[Bezafibrate-induced myolysis and myoglobinuria in patients with impaired renal function]

1 reference

https://api.crossref.org/works/10.1016%2FS0378-4274%2802%2900010-3

7 January 2021

Clofibrate myopathy: a case report and a review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS0378-4274%2802%2900010-3

7 January 2021

Tolerability of fibric acids. Comparative data and biochemical bases.

1 reference

https://api.crossref.org/works/10.1016%2FS0378-4274%2802%2900010-3

7 January 2021

Clofibrate-induced myopathy in the rat

1 reference

https://api.crossref.org/works/10.1016%2FS0378-4274%2802%2900010-3

7 January 2021

Effects of exercise and lovastatin on serum creatine kinase activity

1 reference

https://api.crossref.org/works/10.1016%2FS0378-4274%2802%2900010-3

7 January 2021

[Does hypothyroidism predispose muscular toxicity of fibrates?]

1 reference

https://api.crossref.org/works/10.1016%2FS0378-4274%2802%2900010-3

7 January 2021

Lovastatin-induced rhabdomyolysis in the absence of concomitant drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0378-4274%2802%2900010-3

7 January 2021

Myositis, hypothyroidism and fibrates

1 reference

https://api.crossref.org/works/10.1016%2FS0378-4274%2802%2900010-3

7 January 2021

Effects of gemfibrozil and other fibric acid derivatives on blood lipids and lipoproteins

1 reference

https://api.crossref.org/works/10.1016%2FS0378-4274%2802%2900010-3

7 January 2021

10.1016/S0378-4274(02)00010-3

Identifiers

DOI

1 reference

2 August 2017

1 reference

PubMed ID

11869826